Cross Border Biotech Blog

Bloom Burton & Co. is Canada's leading biotechnology and healthcare-specialized investment banking firm, which exists to accelerate returns in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial approach, leads to the right monetization events for companies and investors. Bloom Burton provides capital raising, M&A advisory, equity research, management consulting, direct investments through equity and debt funds, and company creation services.

Visit Blog

Authors

Wayne Schnarr

Wayne Schnarr advises Bloom Burton in the areas of corporate strategy, capital markets and pharmaceutical product commercialization. For more than 30 years, Wayne has assessed hundreds of technologies, products, business plans and companies in the biotechnology, pharmaceutical and financial sectors. He has been involved in industrial process development, manufacturing of biologics and diagnostics, licensing, and policy formation. In the financial sector, Wayne was an analyst with four Canadian securities dealers, a founder and partner in the venture management firm BioCatalyst Yorkton, and leader of the healthcare investor relations team at The Equicom Group, and has served as a biotechnology company officer and director.

Brian Bloom

Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Institutional Sales. Brian is a member of the Life Sciences Advisory Board at the National Research Council of Canada and also serves on the Board of Directors at BIOTECanada, the Baycrest Foundation. Brian is also the Chairman of the Board of Triumvira Immunologics and Appili Therapeutics and on the Board of Directors of Grey Wolf Animal Health and Qing Bile Therapeutics. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics.

Awards & Publications

** He writes most frequently for blog

Latest Articles

Statement on the postponement of the 2020 Bloom Burton & Co. Healthcare Investor Conference

Statement on the postponement of the 2020 Bloom Burton & Co. Healthcare Investor Conference At Bloom Burton, the safety and well-being of everyone in our healthcare community is our greatest concern. Given the accelerating spread and severity of the...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and ove...

Appili Therapeutics Announces Closing of Public Offering of $10,250,000

Appili Therapeutics Announces Closing of Public Offering of $10,250,000 Original press release here HALIFAX, Nova Scotia, February 20, 2020 – Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) is pleased to announce the cl...

Scott Gottlieb M.D. Announced as the Keynote Speaker for 2020 Bloom Burton & Co. Healthcare Investor Conference

Scott Gottlieb M.D. Announced as the Keynote Speaker for 2020 Bloom Burton & Co. Healthcare Investor Conference Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work foc...

Canada in Science – February 7, 2020

Welcome to your Canada in Science Review for February 7th, 2020! Science.  2020. Jan 17; 367(6475): 301-305 Lipid-gated monovalent ion fluxes regulate endocytic traffic and support immune surveillance Nat Cell Bio.  2020 Jan; 22(1): 120-134. ...